Biosimilar infliximab: An expert view

A. Genazzani, G. Altomare, N. Balato, F. Cusano, O. Depità, F. Loconsole, G. Micali, S. Piaserico, G. Girolomoni

Research output: Contribution to journalArticlepeer-review


CT-P13, a biosimilar of infliximab, was the first biosimilar monoclonal antibody to be approved in both the European Union and Korea. As a monoclonal antibody, CT-P13 is a large molecule with a high molecular weight, and as such it differs from other biosimilars currently in the market. The comparability exercise for CT-P13, therefore, requires special consideration, as it was the first demonstration of biosimilarity between a biosimilar monoclonal antibody and its originator. This paper summarizes current regulations on the approval of biosimilars, describes the evidence leading to the approval of CT-P13, and discusses the potential role of this molecule in the Italian scenario on the basis of the view of a group of experts.

Original languageEnglish
Pages (from-to)449-459
Number of pages11
JournalGiornale Italiano di Dermatologia e Venereologia
Issue number4
Publication statusPublished - Aug 1 2015


  • Ankylosing
  • Arthritis
  • Biosimilar pharmaceuticals
  • Dermatology
  • Infliximab
  • Rheumatoid
  • Spondylitis

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Biosimilar infliximab: An expert view'. Together they form a unique fingerprint.

Cite this